Read the Council’s
New White Paper
Breaking Through on Biosimilars:
Delivering More-Affordable,
Innovative Medicines to America’s Patients
Read the Council’s
The Biosimilars Council
is a division of the Association for Accessible Medicines, formerly known as GPhA, that works to ensure a positive regulatory, reimbursement, political and policy environment for biosimilar products, and is educating the public and patients about the safety and effectiveness of biosimilars.
Where should you get started?
The Council publishes a number of resources to promote knowledge around the advancement of biosimilars, but we would recommend starting with our Handbook – a complete resource on biosimilars in the United States.
Additionally, consider joining us for Access! 2019 – AAM’s annual meeting that gathers industry leaders together to explore the business, the science, the technology, and the politics surrounding our industry.
What are biosimilars?
Put simply, biosimilars are biologic medicines that are highly similar to a corresponding brand biologic. Biosimilars offer a safe, effective, and affordable alternative for patients. They are approved by the U.S. Food and Drug Administration (FDA) and improve patient access to life-saving medicines.
Reports, videos, news sources, and more. Take some time to learn all about biosimilars and the benefits they offer US consumers.
Take a minute and learn all about biosimilars and our industry in an easy to digest format. The best part? It’s free.
We are always on the road advocating for biosimilars and invite you to join us. Check out the details for our next event and bring your friends.
